Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Andrew C JohnsMatthew T CampbellMamie GaoAndrew W HahnZita LimEmily WangJianjun GaoAmishi Y ShahPavlos MsaouelNizar M TannirPublished in: The oncologist (2024)
In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.